• Welcome to the RLT Hub. Image of a scientist looking at a 3d model of peptide receptor radionuclide therapy.
    Welcome to the RLT Hub
    The RLT Hub was developed by Novartis, to provide information to UK health professionals interested in radioligand therapy (RLT) to support the management of their patients with neuroendocrine tumours (NET) and prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC).

The RLT Hub is your guide to understanding GEP-NETs, PSMA positive mCRPC and RLT

Great Britain Prescribing information for Pluvicto®▼(lutetium [177Lu] vipivotide tetraxetan) can be found here.

Northern Ireland Prescribing information for Pluvicto®▼(lutetium [177Lu] vipivotide tetraxetan) can be found here.

Prescribing information for Lutathera® (lutetium [177Lu] oxodotreotide) can be found here.

 

The RLT Hub was developed by Novartis, to provide information to UK health professionals interested in radioligand therapy (RLT) to support the management of their patients with neuroendocrine tumours (NET) and prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC).

Site features

This site provides you with the relevant information and resources to guide your knowledge and understanding of GEP-NET, PSMA positive mCRPC and RLT.

Clinical information on Lutathera and GEP-NETs practical resources for GB healthcare professionals.
This information is intended for healthcare professionals in GB only.
Explore the goals and mechanism of action of this innovative cancer therapy.

GEP, gastroenteropancreatic; mCRPC, metastatic castration-resistant prostate cancer; NET, neuroendocrine tumour; PSMA, prostate-specific membrane antigen; RLT, radioligand therapy

AAA-Lu177-UK-2430 | May 2024
×

Ask Speakers

×

Medical Information Request